Issue link: http://osercommunicationsgroup.uberflip.com/i/668578
C h a i n D r u g s t o r e D a i l y S u n d a y, A p r i l 1 7 , 2 0 1 6 4 CAMBER'S ANTI-RETROVIRAL COMMITMENT RUNS DEEP Camber's parent company, Hetero Drugs, is one of the world's largest producers of anti-retroviral (ARV) finished formula- tions and APIs. The company's commit- ment to HIV/AIDS treatment started way back in 1997, being the first company to develop affordable APIs for anti-retrovi- ral finished formulations. Today, it is rec- ognized as a world leader in providing HIV/AIDS treatment. Approximately 4.5 million HIV/AIDS patients receive ARV formu- lations manufactured by Hetero in its USFDA and WHO approved facilities. Besides the finished formulations, Hetero also supplies APIs to several finished dosage manufacturing companies con- tributing to treatment of an additional 7,000,000 patients worldwide. This means that about one third of the total 11.5 million HIV/AIDS patients under treatment are using API and formulations produced by Hetero. Increased R&D and Manufacturing Facilities Hetero is committed to increasing R&D and manufacturing capacities to meet the demands of the millions of patients that are still deprived of access to treatment. Today, Hetero has built a strong product portfolio of more than 30 ARV combina- tions and has been offering them to patients at an affordable cost. In order to ensure greater access to life-saving medicines, Hetero has also entered into licensing agreements with innovator companies. This has enabled it to manufacture and market newly launched drugs and combination thera- pies to expand access to better and newer treat- ment options in developing coun- tries. It works with Ministries of Health and international aid agencies like UNICEF, PAHO, CHAI, IDA Foundation and WHO in order to make medicines available to patients who are in need. To sum it up, Kon Ostaficiuk, President of Camber Pharmaceuticals, had this to say about Hetero's commitment to anti- retroviral medications: "Our Chairman B.P.S.Reddy of Hetero Drugs likes to remind us that we are in the life-saving business, and we believe not only in the survival of our patients but also in a supe- rior quality of life." Visit Camber Pharmaceuticals at booth #534. For more information, call 732.529. 0430 or go to www.camberpharma.com. GIVE CUSTOMERS A POSITIVE EXPERIENCE WITH WESTROCK WestRock provides pharmacies and phar- maceutical manufacturers with unique award-winning packaging solutions that are designed to improve patient adherence to medication, enhance pharmacy efficiencies and increase speed to market. Shellpak ® Renew and Doseapak ® , top-selling adher- ence solutions, protect medication integrity and offer superior child safety (F=1), while remaining easy for adults to use. An inno- vative capability under the new WestRock organization is merchandising displays, which help drive promotion at the retail set- ting with temporary promotional and per- manent point-of-purchase displays. Providing an end-to-end marketing, merchandising and packaging suite of solutions, WestRock supports the retail pharmacy's challenges comprehensively. Adherence packaging solutions not only maximize pharmacist-patient interaction opportunities, but also provide increased opportunities to satisfy CMS Star ratings and boost reimbursement. Merchandising displays amplify the investment many retail pharmacies have made in mobile app technology, in-store promotions and point of sale prospects by creating a uni- fied customer experience. In-short, WestRock can provide retail customers a positive "in-store" and "at-home" Health and Wellness experience. How the Consumer Journey Comes Together Your customer enters the retail store to sues, and proceeds to checkout. Visit WestRock at booth #562. For more information, contact Ken Bertram, Senior Director, Healthcare Retail Segment at 919.265.3875, or contact Dave Dwyer, Vice President Global Marketing, Adherence at 804.444.7362. pick up a prescription from the pharmacy. Notifications of in-store promotions appear on the patient's mobile device through the retail app. The customer makes a note to pick up the over-the-counter allergy medica- tion being promoted, after remember- ing their child's allergy attack the night before. The customer proceeds to the pharmacy where they have a mean- ingful educational interaction with the pharmacist, who explains their choles- terol medication regimen and side effects, and the importance of compli- ance to maximize symptom improve- ment with a calendar blister package. The consumer then goes to pick up their allergy medication from the WestRock promotional display. Finally, the customer pulls an in-store coupon off the display for $2 off tis- AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Lee M. Oser CEO and Editor-in-Chief Jules Denton Kim Forrester Delaney Oser Associate Publishers Lorrie Baumann Editorial Director Jeanie Catron JoEllen Lowry Associate Editors André Gressieux Art Director Yasmine Brown Krystal Robles Graphic Designers Caitlyn McGrath Sarah Glenn Customer Service Managers Stacy Davis Kim Stevens Show Logistics & Distribution James Gennette John Pechota Carlos Velasquez Account Managers Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2016 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 www.osercommunicationsgroup.com European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy MALLINCKRODT PHARMACEUTICALS: INVESTING IN THE FUTURE For nearly 150 years, the Mallinckrodt name has represented quality products, business integrity and service to patients, customers and communities. Its future- focused vision and dedication to improv- ing lives is matched only by its distinct approach to managing complexity. Today, Mallinckrodt Pharmaceuticals is a specialty biopharmaceutical company that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare dis- eases in specialty areas like neurology, rheumatology, nephrology and pul- monology; immunotherapy and neonatal respiratory critical care therapies; anal- gesics and hemostasis products; and cen- tral nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The compa- ny's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients (APIs) and external manufac- turing; and the Nuclear Imaging segment includes radiopharmaceutical agents. Mallinckrodt continues to apply its unique strengths, experience and expertise to bring products to the market that provide value for physicians as well as patients. Specialty Generics Leader Mallinckrodt's Specialty Generics busi- ness developed as an extension of the company's API platform in the mid- 1990s. Today, its Specialty Generics seg- ment includes a robust portfolio of con- trolled substances for pain management, substance abuse and attention-deficit hyperactivity disorders. It manufactures APIs for its products as well as for some of the world's most recognized compa- nies; it is also one of the world's leading producers of bulk acetaminophen. Mallinckrodt's Specialty Generics business is vertically integrated, enabling internal quality control during every step of a product's development. Through its glob- al operations platform, its ability to manufac- ture complex products and deliver them effi- ciently to customers reflects Mallinckrodt's core values that have held true since 1867 – quality, integrity and service. Investing in the Future The same goal of providing high-quality, innovative products that began almost a century and a half ago with the Mallinckrodt brothers still exists today. At Mallinckrodt, it applies its acquire to invest business model to key product port- folios like Specialty Generics. For exam- ple, that business has benefited from a skilled Research and Development (R&D) team. The company's development pipeline remains focused in areas where it believes it can bring differentiated value to the marketplace, and the Specialty Generics R&D projects are a high priority. The company has also invested mil- lions of dollars in research efforts focus- ing on exploring the abuse-deterrent potential of its proprietary formulation technologies. Mallinckrodt understands the importance of developing abuse- deterrent technologies for both branded and generic medicines that will effective- ly make products less attractive to poten- tial abusers. At the same time, it remains vitally important to continue providing patients who depend on its medicines with a range of safe, affordable options. The company's supply chain organi- zation continues to invest in several infrastructure and capacity improve- ments, better ensuring consistent delivery of the high-quality products its customers need and expect. In addition, Mallinckrodt has devoted funding to its API business to increase capacity and reliability of raw materials for generic pharmaceuticals – both its own and those of its third-party customers. For its Specialty Generics segment and throughout Mallinckrodt, it remains laser-focused on its mission statement – Managing Complexity. Improving Lives. Its unique strengths provide the founda- tion for managing the complexities inher- ent to its specialty pharmaceutical prod- ucts – particularly controlled substances – and every day it is committed to meet- ing the needs of patients, delivering value toward improving their lives. Visit Mallinckrodt Pharmaceuticals at booth #318. For more information, call 800.325. 8888 or go to www.mallinckrodt.com.